Skip to main content

Table 2 Clinic Characteristics of the Subjects

From: A stepwise data interpretation process for renal amyloidosis typing by LMD-MS

  Training set Validation set Non-amyloid nephropathy
DN FGN IgAN LN MN NAT
Age (years) 60.0 (52.0–64.0) 61.0 (51.8–67.3) 56.0 (51.0–60.0) 43.0 (39.0–46.8) 41.0 (31.0–42.0) 34.0 (29.0–38.0) 51.0 (45.0–56.0) -
Gender (male/female) 22/20 31/19 6/7 2/6 3/6 0/5 12/3 5a
Upro (mg/day) 3482 (1731–7490) 3716 (2755–5687) 3835 (2658–8013) 3480 (2740–5340) 1060 (815–1690) 3583 (2142–6214) 3984 (3720–4248) -
Alb (g/L) 22.9 (17.8–28.3) 25.7 (20.7–29.3) 27.4 (25.1–32.2) 31.8 (28.9–33.4) 38.8 (38.7–39.0) 26.2 (24.0–29.7) 16.8 (15.8–17.7) -
Scr (μmol/L) 84.0 (58.0–141.0) 85.0 (68.5–100.0) 108.0 (60.0–191.0) 64.0 (57.0–99.0) 82.0 (67.0–92.0) 64.0 (59.0–68.0) 93 (85.5–100.5) -
BUN (mmol/L) 6.0 (5.4–9.0) 7.3 (4.5–9.2) 5.4 (4.4–7.7) 4.7 (3.3–6.2) 5.6 (5.2–7.0) 5.4 (3.6–5.5) 5.0 (3.4–5.8) -
  1. aClinical information of NAT specimen was not collected
  2. Data are presented as median with interquartile range
  3. Upro urine protein, Alb albumin, Scr serum creatinine, BUN blood urea nitrogen